tripterygium wilfordii
ApprovedSmall molecule
tripterygium wilfordii is one of 109 small molecule programs targeting Focal Segmental Glomerulosclerosis. It is currently in Approved.
4
Indications
5
Total Trials
0
Active Trials
108
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
75 competitors in Membranous Nephropathy
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Neoral
NovartisPhase 3
Gazyva
RochePhase 3
Medrol
PfizerPhase 3
Prograf
VVeloxis Pharmaceuticals
Phase 3
Brukinsa
BBeOne Medicines
Phase 3
tripterygium wilfordii
ZZhi-Hong Liu, M.D.
Approved
Felzartamab
BiogenPhase 3
Benadryl
PParkedale
Phase 3
Tylenol
KKenvue Brands
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Autosomal Dominant Polycystic Kidney Disease1 trial
Pterygium1 trial
Membranous Nephropathy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for tripterygium wilfordii. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- ZZhi-Hong Liu, M.D.